Ferroptosis inducer erastin counteraction experiment

Exploratory Score: 0.800 Price: $0.50 sepsis-associated acute lung injury RAW264.7 cells and/or mouse model Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting N/A in RAW264.7 cells and/or mouse model. Primary outcome: reversal of acteoside's protective effects

Description

This mechanistic validation experiment used erastin, a known ferroptosis inducer, to test whether the protective effects of acteoside could be reversed by promoting ferroptosis. The experiment was designed to confirm that acteoside's beneficial effects in SALI are specifically mediated through ferroptosis inhibition. Researchers likely treated cells or animals with acteoside along with erastin to demonstrate that inducing ferroptosis would counteract acteoside's protective benefits. This approach provided crucial evidence that ferroptosis is indeed the primary pathway through which acteoside exerts its protective effects against sepsis-associated lung injury.

TARGET GENE
N/A
MODEL SYSTEM
RAW264.7 cells and/or mouse model
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
ferroptosis pathway
SOURCE
extracted_from_pmid_41895086
PRIMARY OUTCOME
reversal of acteoside's protective effects

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.800 composite

📖 Wiki Pages

FerroptosisentityResearchersindexFerroptosis in Neurodegenerationmechanism

Protocol

co-treatment with acteoside and erastin, assessment of protective effects

Expected Outcomes

erastin counteracts acteoside's benefits

Success Criteria

loss of acteoside's protective effects when ferroptosis is induced

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.